Recce Pharmaceuticals patent achievement

Recce Pharmaceuticals (ASX:RCE) has achieved a significant milestone by securing an Australian patent for Patent Family 3, offering protection for its anti-infective products RECCE® 327 and RECCE® 529. This patent ensures coverage across major pharmaceutical markets including the USA, Europe, China, and Japan, and is valid until 2037.

Recce Pharmaceuticals patent announcement overview

Recce Pharmaceuticals has secured global patent protection for its anti-infective products, RECCE® 327 and RECCE® 529, until 2037. The patent covers manufacturing processes and administration methods, reinforcing Recce’s intellectual property strategy in key markets. RECCE® 327 is targeted at bacterial infections, including antibiotic-resistant superbugs, while RECCE® 529 aims to treat viral infections. The World Health Organization and FDA have recognized the importance of these products, with R327 receiving a Qualified Infectious Disease Product designation. Recce continues to develop its pipeline, addressing unmet medical needs with unique technological advancements.

Insights from Recce Pharmaceuticals leadership

We are thrilled to have the Australian patent granted, which is a testament to our commitment to addressing significant viral and bacterial threats globally,' said CEO James Graham.